The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection

Lin, Philana Ling; Dietrich, Jes; Tan, Esterlina; Abalos, Rodolfo M.; Burgos, Jasmin; Bigbee, Carolyn; Bigbee, Matthew; Milk, Leslie; Gideon, Hannah P.; Rodgers, Mark; Cochran, Catherine; Guinn, Kristi M.; Sherman, David R.; Klein, Edwin; Janssen, Christopher; Flynn, JoAnne L.; Andersen, Peter
January 2012
Journal of Clinical Investigation;Jan2012, Vol. 122 Issue 1, p303
Academic Journal
It is estimated that one-third of the world's population is infected with Mycobacterium tuberculosis. Infection typically remains latent, but it can reactivate to cause clinical disease. The only vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), is largely ineffective, and ways to enhance its efficacy are being developed. Of note, the candidate booster vaccines currently under clinical development have been designed to improve BCG efficacy but not prevent reactivation of latent infection. Here, we demonstrate that administering a multistage vaccine that we term H56 in the adjuvant IC31 as a boost to vaccination with BCG delays and reduces clinical disease in cynomolgus macaques challenged with M. tuberculosis and prevents reactivation of latent infection. H56 contains Ag85B and ESAT-6, which are two of the M. tuberculosis antigens secreted in the acute phase of infection, and the nutrient stress-induced antigen Rv2660c. Boosting with H56/IC31 resulted in efficient containment of M. tuberculosis infection and reduced rates of clinical disease, as measured by clinical parameters, inflammatory markers, and improved survival of the animals compared with BCG alone. Boosted animals showed reduced pulmonary pathology and extrapulmonary dissemination, and protection correlated with a strong recall response against ESAT-6 and Rv2660c. Importantly, BCG/H56-vaccinated monkeys did not reactivate latent infection after treatment with anti-TNF antibody. Our results indicate that H56/IC31 boosting is able to control late-stage infection with M. tuberculosis and contain latent tuberculosis, providing a rationale for the clinical development of H56.


Related Articles

  • Immunity to Mycobacterium tuberculosis. Triccas, James A.; Winter, Nathalie; Feng, Carl G.; West, Nicholas P. // Clinical & Developmental Immunology;2011, p1 

    In this article the author discusses the need to better understand the host response to Mycobacterium tuberculosis and develop effective methods to control Tuberculosis (TB). The author tells that various TB research programs aim to develop new vaccines. The author also discusses various article...

  • Contraindicated BCG vaccination in "at risk" infants. Rees, Philippa; Evans, Huw; Panesar, Sukhmeet; Llewelyn, Meirion; Edwards, Adrian; Carson-Stevens, Andrew // BMJ: British Medical Journal;9/13/2014, Vol. 349 Issue 7974, p20 

    A letter to the editor is presented in response to the article "Effect of BCG Vaccination Against Mycobacterium Tuberculosis Infection in Children: Systematic Review and Meta-Analysis" by A. Roy and colleagues in the August 5, 2014 issue.

  • Tuberculosis and bacille-calmette-guerin vaccination.  // MMWR: Morbidity & Mortality Weekly Report;12/26/1997 Supplement RR-18, Vol. 46, p13 

    Focuses on the use of the bacille calmette-guerin (BCG) vaccine for infection with Mycobacterium tuberculosis (TB) in the United States. Reason BCG is not recommended to general use; Strategies for the prevention and control of TB; Information on the role of the BCG vaccination in the...

  • BCG and infection with Mycobacterium tuberculosis. Turner, Richard D.; Tweed, Conor D.; Shukla, Jilna; Bothamley, Graham H.; Michelsen, S. W.; Agger, E. M.; Hoff, S. T.; Soborg, B.; Carstensen, L.; Koch, A.; Lillebaek, T.; Sorensen, H. C. F.; Wohlfahrt, J.; Melbye, M. // Thorax;Mar2015, Vol. 70 Issue 3, p286 

    A letter to editor is presented in response to the article "The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland" by S. W. Michelsen, B. Soborg and colleagues in the 2014 issue.

  • Tuberculin Skin Reactivity in Italian Military Recruits Tested in 1996–1997. D'Amelio, R.; Stroffolini, T.; Biselli, R.; Molica, C.; Cotichini, R.; Bernardini, G.; Vellucci, A. // European Journal of Clinical Microbiology & Infectious Diseases;Mar2000, Vol. 19 Issue 3, p200 

    In 1996–1997 data was collected and a Mantoux tuberculin test performed in 2882 Italian military recruits aged 18–23 years in order to establish the prevalence of tuberculin reactivity. In addition, the annual risk of infection, defined as the probability that a non-infected...

  • Tuberculosis vaccines: time to reset the paradigm? Lalvani, Ajit; Sridhar, Saranya; von Reyn, C. Fordham // Thorax;Dec2013, Vol. 68 Issue 12, p1092 

    The article focuses on the phase IIb efficacy trial of the tuberculosis vaccine candidate MVA85A as of December 2013. It informs that MVA85A is a modified vaccinia virus expressing the mycobacterium tuberculosis (MTB) 85A antigen designed to improve on the currently available vaccine bacillus...

  • Vaccines: A souped-up version of BCG. Bell, Elaine // Nature Reviews Immunology;Oct2005, Vol. 5 Issue 10, p746 

    Discusses research being done on the increased protection against pulmonary tuberculosis from modified versions of the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine. Reference to the study by Leander Grode and colleagues published in a 2005 issue of the "Journal of Clinical...

  • Predictors of Positive Tuberculin Skin Test (TST) Results after 2-Step TST among Health Care Workers in Manitoba, Canada. Kraut, Allen; Coodin, Michael; Plessis, Rose; McLean, Dana // Clinical Infectious Diseases;12/1/2004, Vol. 39 Issue 11, pe113 

    Background. Baseline 2-step tuberculin skin testing (TST) is recommended for health care workers (HCWs) to identify cases of the "boosting phenomenon" (i.e., a negative initial TST result followed by a positive result) and to track the risk of acquiring occupational tuberculosis. However, the...

  • Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice. Jiu ling Wang; Ya qing Qie; Bing dong Zhu; Hong mei Zhang; Ying Xu; Qing zhong Wang; Jia zhen Chen; Wei Liu; Hong hai Wang // Medical Microbiology & Immunology;Feb2009, Vol. 198 Issue 1, p5 

    Antigen 85B (Ag85B) is an important immunodominant antigen of Mycobacterium tuberculosis, and is a very promising vaccine candidate molecule. Rv3425 is a member of the subgroup 3 of the PPE family, which does not exist in all BCG strains. In this study we constructed a new rBCG which included...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics